Mazor CEO Ori Hadomi mentioned in the 2017 earnings call earlier this week the company is pivoting efforts for its Renaissance robotic spine surgery system to target the ASC market, according to a transcript published in Seeking Alpha.
"Our primary focus for the Renaissance is the ambulatory surgery center, or ASCs, a market segment that we believe will take advantage of the system's value pricing," said Mr. Hadomi. The company will continue to target the inpatient hospital market with its next-generation robotic technology, Mazor X, along with innovation development and marketing partner Medtronic.
The company has an ambitious outlook on the market.
"In the U.S., we believe there are approximately 1,000 ASCs that would benefit from using the Renaissance system," said Mr. Hadomi. "At the same time, we don't believe this will cannibalize any Mazor X system sales due to the case volume and system costs."